HKSE - Delayed Quote HKD

Fangzhou Inc. (6086.HK)

1.040 +0.035 (+3.48%)

As of 1:23:45 PM GMT+8. Market Open.

Fangzhou Receives Outstanding Brand Accolade at the 14th Capital Power Annual Awards for AI Chronic Care Innovation

GlobeNewswire 3h ago

6086.HK
+3.48%
Fangzhou Honored with Digital Intelligence Leadership Award at Tencent Summit, Expands Healthcare AI Partnership with Tencent Health

GlobeNewswire 9d ago

6086.HK
+3.48%
0700.HK
Fangzhou Showcases Award-Winning AI Chronic Care Solution at Fortune China 500 Forum

GlobeNewswire 17d ago

6086.HK
+3.48%
Fangzhou and Cutia Therapeutics Partner to Advance AI-Powered Dermatology and Chronic Health Management

GlobeNewswire 20d ago

6086.HK
+3.48%
Fangzhou Releases 2026 Interim Report, Deepening "AI + Chronic Care" as a Lifetime Health Service Partner

GlobeNewswire 1mo ago

6086.HK
+3.48%
Fangzhou’s AI-Powered Chronic Care Model Named to Fortune China’s Best Designs 2026

GlobeNewswire 2mo ago

6086.HK
+3.48%
6086
Fangzhou Reports Sustained Revenue and Profit Growth as AI-Powered Chronic Care Strategy Gains Momentum

GlobeNewswire 2mo ago

6086.HK
+3.48%
6086
Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China

GlobeNewswire 3mo ago

6086.HK
+3.48%
NVO
Fangzhou Named to KPMG China Healthcare 50 for AI-Powered Chronic Disease Care

GlobeNewswire 3mo ago

6086.HK
+3.48%
6086
Fangzhou Showcases AI-Powered Chronic Disease Management Solution With Tencent Health at Tencent Cloud Conference

GlobeNewswire 5mo ago

6086.HK
+3.48%
Fangzhou Showcases “AI+H2H” Chronic Disease Service Innovations at the National Intelligent Medicine Conference

GlobeNewswire 5mo ago

6086.HK
+3.48%
Fangzhou Publishes 2025 Annual Report, Advancing AI-Powered Chronic Care Strategy for 2026

GlobeNewswire 6mo ago

6086.HK
+3.48%

U.S. markets open in 8h 21m

Fangzhou Inc. (6086.HK)

Fangzhou Receives Outstanding Brand Accolade at the 14th Capital Power Annual Awards for AI Chronic Care Innovation

Fangzhou Honored with Digital Intelligence Leadership Award at Tencent Summit, Expands Healthcare AI Partnership with Tencent Health

Fangzhou Showcases Award-Winning AI Chronic Care Solution at Fortune China 500 Forum

Fangzhou and Cutia Therapeutics Partner to Advance AI-Powered Dermatology and Chronic Health Management

Fangzhou Releases 2026 Interim Report, Deepening "AI + Chronic Care" as a Lifetime Health Service Partner

Fangzhou’s AI-Powered Chronic Care Model Named to Fortune China’s Best Designs 2026

Fangzhou Reports Sustained Revenue and Profit Growth as AI-Powered Chronic Care Strategy Gains Momentum

Fangzhou Launches Novo Nordisk’s Once-Weekly Basal Insulin/GLP-1 Therapy in China

Fangzhou Named to KPMG China Healthcare 50 for AI-Powered Chronic Disease Care

Fangzhou Showcases AI-Powered Chronic Disease Management Solution With Tencent Health at Tencent Cloud Conference

Fangzhou Showcases “AI+H2H” Chronic Disease Service Innovations at the National Intelligent Medicine Conference

Fangzhou Publishes 2025 Annual Report, Advancing AI-Powered Chronic Care Strategy for 2026